Single User License
INR 236460
Site License
INR 472920
Corporate User License
INR 709380

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Pipeline Review, H2 2016

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Pipeline Review, H2 2016', provides in depth analysis on Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Overview 8

Therapeutics Development 9

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Products under Development by Stage of Development 9

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Products under Development by Therapy Area 10

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Products under Development by Indication 11

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Products under Development by Companies 15

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Products under Development by Universities/Institutes 23

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Therapeutics Assessment 25

Assessment by Monotherapy/Combination Products 25

Assessment by Mechanism of Action 26

Assessment by Route of Administration 27

Assessment by Molecule Type 28

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Companies Involved in Therapeutics Development 30

AbbVie Inc 30

ACEA Biosciences, Inc. 32

Advinus Therapeutics Ltd 33

ArQule, Inc. 34

BeiGene, Ltd. 35

Beijing Hanmi Pharmaceutical Co Ltd 36

Biogen Inc 37

Bristol-Myers Squibb Company 38

Celgene Corporation 39

CrystalGenomics, Inc. 40

Genentech, Inc. 41

Hanmi Pharmaceuticals, Co. Ltd. 42

LSK BioPartners, Inc. 43

Merck KGaA 44

Ono Pharmaceutical Co., Ltd. 45

Pharmacyclics, Inc. 46

Principia Biopharma Inc. 47

Redx Pharma Plc 48

Simcere Pharmaceutical Group 49

Sunesis Pharmaceuticals, Inc. 50

Takeda Pharmaceutical Company Limited 51

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Drug Profiles 52

ABBV-599-Drug Profile 52

AC-058-Drug Profile 53

acalabrutinib-Drug Profile 54

Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia-Drug Profile 57

ARQ-531-Drug Profile 58

BGB-3111-Drug Profile 59

BIIB-068-Drug Profile 62

BMS-986142-Drug Profile 63

BMS-986195-Drug Profile 64

CG-026806-Drug Profile 65

CG-036806-Drug Profile 66

Drug to Inhibit BTK for Undisclosed Indications-Drug Profile 67

DTRMWXHS-12-Drug Profile 68

EBI-1266-Drug Profile 69

EBI-1367-Drug Profile 70

HCI-1401-Drug Profile 71

HCI-1684-Drug Profile 72

HM-71224-Drug Profile 73

ibrutinib-Drug Profile 74

M-2951-Drug Profile 97

M-7583-Drug Profile 98

ONO-4059-Drug Profile 99

PLS-123-Drug Profile 101

PNQ-154-Drug Profile 102

PNQ-849-Drug Profile 103

PRN-1008-Drug Profile 104

PRN-473-Drug Profile 106

RDX-002-Drug Profile 107

RG-7845-Drug Profile 108

Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis-Drug Profile 109

Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders and Rheumatoid Arthritis-Drug Profile 110

Small Molecule to Inhibit BTK for Immunology-Drug Profile 111

Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer-Drug Profile 112

Small Molecule to Inhibit BTK for Oncology-Drug Profile 113

Small Molecule to Target BTK for Immunology-Drug Profile 114

Small Molecules to Inhibit BTK for Oncology-Drug Profile 115

Small Molecules to Inhibit BTK for Rheumatoid Arthritis-Drug Profile 116

SNS-062-Drug Profile 118

spebrutinib besylate-Drug Profile 120

TAK-020-Drug Profile 122

X-022-Drug Profile 123

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Dormant Projects 124

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Discontinued Products 127

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)-Featured News & Press Releases 128

Appendix 140

Methodology 140

Coverage 140

Secondary Research 140

Primary Research 140

Expert Panel Validation 140

Contact Us 140

Disclaimer 141

List of Figures

Number of Products under Development for, H2 2016 12

Number of Products under Development by Therapy Area, H2 2016 13

Number of Products under Development by Top 10 Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 31

List of Tables

Number of Products under Development for, H2 2016 12

Number of Products under Development by Therapy Area, H2 2016 13

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Development by Companies, H2 2016 (Contd..2) 21

Products under Development by Companies, H2 2016 (Contd..3) 22

Products under Development by Companies, H2 2016 (Contd..4) 23

Products under Development by Companies, H2 2016 (Contd..5) 24

Products under Development by Companies, H2 2016 (Contd..6) 25

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Products under Investigation by Universities/Institutes, H2 2016 27

Assessment by Monotherapy/Combination Products, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Pipeline by AbbVie Inc, H2 2016 34

Pipeline by ACEA Biosciences, Inc., H2 2016 35

Pipeline by Advinus Therapeutics Ltd, H2 2016 36

Pipeline by ArQule, Inc., H2 2016 37

Pipeline by BeiGene, Ltd., H2 2016 38

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 39

Pipeline by Biogen Inc, H2 2016 40

Pipeline by Bristol-Myers Squibb Company, H2 2016 41

Pipeline by Celgene Corporation, H2 2016 42

Pipeline by CrystalGenomics, Inc., H2 2016 43

Pipeline by Genentech, Inc., H2 2016 44

Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 45

Pipeline by LSK BioPartners, Inc., H2 2016 46

Pipeline by Merck KGaA, H2 2016 47

Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 48

Pipeline by Pharmacyclics, Inc., H2 2016 49

Pipeline by Principia Biopharma Inc., H2 2016 50

Pipeline by Redx Pharma Plc, H2 2016 51

Pipeline by Simcere Pharmaceutical Group, H2 2016 52

Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 53

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 54

Dormant Projects, H2 2016 127

Dormant Projects (Contd..1), H2 2016 128

Dormant Projects (Contd..2), H2 2016 129

Discontinued Products, H2 2016 130

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, ACEA Biosciences, Inc., Advinus Therapeutics Ltd, ArQule, Inc., BeiGene, Ltd., Beijing Hanmi Pharmaceutical Co Ltd, Biogen Inc, Bristol-Myers Squibb Company, Celgene Corporation, CrystalGenomics, Inc., Genentech, Inc., Hanmi Pharmaceuticals, Co. Ltd., LSK BioPartners, Inc., Merck KGaA, Ono Pharmaceutical Co., Ltd., Pharmacyclics, Inc., Principia Biopharma Inc., Redx Pharma Plc, Simcere Pharmaceutical Group, Sunesis Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com